### Ceftriaxone

**Indication**
- Other specified pneumonia
  - ICD11 code: CA40.Y

**INN**
- Ceftriaxone

**Medicine type**
- Chemical agent

**Antibiotic groups**
- WATCH

**List type**
- Core

**Additional notes**
- Do not administer with calcium and avoid in infants with hyperbilirubinaemia.

**Formulations**
- Parenteral > General injections > unspecified:
  - 250 mg in vial powder for injection (as sodium salt);
  - 1 g in vial powder for injection (as sodium salt);
  - 2 g in vial powder for injection (as sodium salt) (EML);
  - 500 mg in vial powder for injection (as sodium salt).

**EML status history**
- First added in 2017 (TRS 1006)
- Changed in 2021 (TRS 1035)
- Changed in 2023 (TRS 1049)

**Sex**
- All

**Age**
- Also recommended for children

**Age restriction**
- > 41 weeks corrected gestational age

**Therapeutic alternatives**
- The recommendation is for this specific medicine

**Patent information**
- Patents have expired in most jurisdictions
- Read more about patents.

**Wikipedia**
- Ceftriaxone

**DrugBank**
- Ceftriaxone

### Expert Committee recommendation

The Expert Committee recommended the inclusion of a new strength, child-friendly dispersible tablet formulation of amoxicillin + clavulanic acid (200 mg + 28.5 mg) as an Access group antibiotic on the core list of the EMLc for treatment of bacterial infections in children – specifically those infections for which amoxicillin + clavulanic acid is already recommended on the EMLc. The Committee noted that the 7:1 ratio of amoxicillin to clavulanic acid is associated with similar efficacy to the 4:1 ratio but has a reduced frequency of gastrointestinal adverse effects. The Committee endorsed the importance of age-appropriate formulations to better meet the dosing needs of children.

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended:
- the addition of a new formulation of amoxicillin + clavulanic acid (dispersible tablet 250 mg + 62.5 mg) to the EMLc.
- the addition of new strength formulations of cefotaxime (powder for injection: 500 mg; 1 g; 2 g (as sodium) in vial) to the EML and EMLc.
- the addition of a new strength formulation of ceftriaxone (powder for injection: 500 mg (as sodium) in vial) to the EML and EMLc.

### EML recommendations: Other specified pneumonia

**First choice**

**Second choice**
<table>
<thead>
<tr>
<th>Antibiotic Combination</th>
</tr>
</thead>
<tbody>
<tr>
<td>piperacillin + tazobactam</td>
</tr>
<tr>
<td>amoxicillin + clavulanic acid</td>
</tr>
<tr>
<td>cefotaxime</td>
</tr>
<tr>
<td>ceftriaxone</td>
</tr>
</tbody>
</table>